{"entity":{"id":"nct05771584","kind":"trial","name":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer","aka":["CORNERSTONE-003"],"tldr":"A phase 2 trial of AST-301 in gastric & gastro-oesophageal junction cancer, run by Aston Sci. Inc., active and no longer recruiting.","summary":"Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer is a phase 2 interventional study registered as NCT05771584 by Aston Sci. Inc., with 24 participants enrolled, started 2023-07-04 and due to reach its primary completion in 2027-02-09. Interventions recorded: AST-301 and rhuGM-CSF.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05771584","url":"https://clinicaltrials.gov/study/NCT05771584"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","gastric-her2-positive"],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05771584","phase":"2","setting":"A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Expressing Gastric Cancer (CORNERSTONE-003)","sponsor":"Aston Sci. Inc.","started":"2023-07-04","startedType":"actual","enrolled":24,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05771584/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"gastric-her2-positive","kind":"cancer","name":"HER2-positive gastric cancer","route":"/cancers/gastric-her2-positive/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}]}}